Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6680
- TODAY'S CHANGE (%)0.0097 (1.4735%)
- Bid / Lots0.6600/ 1
- Ask / Lots0.6700/ 2
- Open / Previous Close0.6681 / 0.6583
- Day Range
- 52 Week Range
- Volume132,502
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 1094 | 0.6681 |
| 09:36 ET | 100 | 0.66 |
| 09:43 ET | 146 | 0.660161 |
| 09:57 ET | 400 | 0.6603 |
| 09:59 ET | 351 | 0.6681 |
| 10:01 ET | 10209 | 0.6681 |
| 10:03 ET | 917 | 0.6681 |
| 10:08 ET | 100 | 0.6689 |
| 10:12 ET | 2308 | 0.6689 |
| 10:14 ET | 2000 | 0.6685 |
| 10:15 ET | 250 | 0.6657 |
| 10:17 ET | 165 | 0.6662 |
| 10:24 ET | 3300 | 0.6629 |
| 10:28 ET | 1100 | 0.6656 |
| 10:30 ET | 447 | 0.6629 |
| 10:37 ET | 200 | 0.6601 |
| 10:39 ET | 125 | 0.6646 |
| 10:42 ET | 4312 | 0.6601 |
| 10:44 ET | 685 | 0.6615 |
| 10:46 ET | 100 | 0.6616 |
| 10:53 ET | 300 | 0.6601 |
| 10:57 ET | 2869 | 0.660201 |
| 11:02 ET | 5730 | 0.66 |
| 11:06 ET | 1274 | 0.66 |
| 11:11 ET | 1949 | 0.6533 |
| 11:13 ET | 100 | 0.6533 |
| 11:29 ET | 572 | 0.6511 |
| 11:31 ET | 400 | 0.6511 |
| 11:47 ET | 200 | 0.6511 |
| 11:54 ET | 150 | 0.6511 |
| 12:03 ET | 347 | 0.6512 |
| 12:05 ET | 203 | 0.6502 |
| 12:09 ET | 110 | 0.6512 |
| 12:20 ET | 100 | 0.6512 |
| 12:23 ET | 1344 | 0.6512 |
| 12:36 ET | 300 | 0.6533 |
| 12:38 ET | 115 | 0.6582 |
| 12:54 ET | 294 | 0.6583 |
| 01:12 ET | 7197 | 0.6604 |
| 01:26 ET | 200 | 0.6631 |
| 01:28 ET | 378 | 0.6676 |
| 01:35 ET | 358 | 0.66535 |
| 01:39 ET | 123 | 0.665 |
| 02:04 ET | 555 | 0.6631 |
| 02:08 ET | 276 | 0.6648 |
| 02:11 ET | 2523 | 0.6651 |
| 02:13 ET | 1100 | 0.667 |
| 02:18 ET | 1048 | 0.668 |
| 02:22 ET | 300 | 0.6741 |
| 02:27 ET | 200 | 0.6674 |
| 02:29 ET | 100 | 0.67075 |
| 02:38 ET | 7370 | 0.6726 |
| 02:42 ET | 200 | 0.6698 |
| 02:45 ET | 11390 | 0.6671 |
| 02:47 ET | 4267 | 0.6671 |
| 02:49 ET | 234 | 0.6671 |
| 03:02 ET | 634 | 0.6671 |
| 03:14 ET | 1305 | 0.6671 |
| 03:16 ET | 351 | 0.6672 |
| 03:23 ET | 300 | 0.6677 |
| 03:25 ET | 275 | 0.6707 |
| 03:32 ET | 268 | 0.6741 |
| 03:36 ET | 1225 | 0.6675 |
| 03:41 ET | 2249 | 0.67 |
| 03:48 ET | 5542 | 0.6673 |
| 03:52 ET | 7393 | 0.6674 |
| 03:54 ET | 1250 | 0.6677 |
| 03:56 ET | 639 | 0.67 |
| 03:57 ET | 400 | 0.67 |
| 03:59 ET | 9655 | 0.668 |
Jul 10, 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), from 4:01PM ET on Wednesday Jul 10, 2024 by Dow Jones
4:01PM ET on Wednesday Jul 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 47.9M | -0.5x | --- |
LAVA Therapeutics NV | 55.5M | -1.9x | --- |
Atara Biotherapeutics Inc | 47.9M | -0.2x | --- |
DURECT Corp | 51.2M | -1.9x | --- |
Cue Biopharma Inc | 34.2M | -0.6x | --- |
Bolt Biotherapeutics Inc | 28.1M | -0.5x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Chief Executive Officer, Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.9M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 72.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.26 |
EPS | $-1.39 |
Book Value | $2.58 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 6.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,580.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
